Suppr超能文献

[艾滋病相关非霍奇金淋巴瘤患者的临床病理特征及生存情况]

[Clinicpathological features and survival of patients with AIDS related non-Hodgkin's lymphoma].

作者信息

Sun K Y, Gui X E, Deng D, Xiong Y, Deng L P, Gao S C, Zhang Y X

机构信息

Department of Infectious Disease, Zhongnan Hospital of Wuhan University. Wuhan 430071, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2017 Feb 14;38(2):97-101. doi: 10.3760/cma.j.issn.0253-2727.2017.02.003.

Abstract

To analyze the clinical characteristics, pathological features and survival of patients with AIDS related non-Hodgkin's lymphoma (ARL) . The clinical data of 53 ARL cases diagnosed and received care at Zhongnan hospital of Wuhan University were retrospectively studied, and 106 controls were enrolled as control group according to 1∶2 for paired cases and control. SPSS 13.0 package was used for statistical analysis. Kaplan-Meier was applied to assess the survival probability. The mean age of patients with ARL was 43 (11-67) years. Male versus female was approximately 4∶1. The median CD4(+) T cell count was (146±20) /ml. The Ann Arbor clinical classification showed that 52.8% of the cases were of stage Ⅲ and Ⅳ. Approximately 54.7% of the patients had elevated serum lactate dehydrogenase (LDH) . According to international prognosis index score, 64.2% of the patients were in high risk group. Diffuse large B-cell lymphoma (DLBCL) was the predominant histological subtype. Among 53 cases, 33 cases (62.3%) received combination of anti-HIV therapy and anti-NHL (CHOP) chemotherapy regimen, 8 cases (15.1%) only received anti-HIV therapy, and 12 cases (22.6%) asked for alleviative treatment. Median survival time was (6.0±1.3) months for ARL cases versus (48.0±10.0) months for controls (<0.05) . After eliminating cases who did not receive anti-lymphoma treatment, ARL cases showed a lower 1-year OS rates than control group (60.6% versus 83.0%) , but no difference about 2-, 3- and 5-year OS rates (53.5% versus 60.5%, 48.1% versus 45.9%, and 39.1% versus 27.5%, respectively) . ARL is more common in young adults; one-year mortality rate is high. Anti-HIV therapy combined with anti-NHL therapy could significantly improve the prognosis of ARL patients. CHOP regimen may be more suitable for ARL patients.

摘要

分析艾滋病相关非霍奇金淋巴瘤(ARL)患者的临床特征、病理特征及生存情况。回顾性研究了武汉大学中南医院确诊并接受治疗的53例ARL患者的临床资料,并按照1∶2配对病例与对照的方式纳入106例对照作为对照组。采用SPSS 13.0软件包进行统计分析。应用Kaplan-Meier法评估生存概率。ARL患者的平均年龄为43(11 - 67)岁。男女比例约为4∶1。CD4(+) T细胞计数中位数为(146±20)/ml。Ann Arbor临床分期显示,52.8%的病例为Ⅲ期和Ⅳ期。约54.7%的患者血清乳酸脱氢酶(LDH)升高。根据国际预后指数评分,64.2%的患者处于高危组。弥漫性大B细胞淋巴瘤(DLBCL)是主要的组织学亚型。53例患者中,33例(62.3%)接受了抗HIV治疗联合抗非霍奇金淋巴瘤(CHOP)化疗方案,8例(15.1%)仅接受抗HIV治疗,12例(22.6%)要求姑息治疗。ARL患者的中位生存时间为(6.0±1.3)个月,而对照组为(48.0±10.0)个月(<0.05)。排除未接受抗淋巴瘤治疗的病例后,ARL患者的1年总生存率低于对照组(60.6%对83.0%),但2年、3年和5年总生存率无差异(分别为53.5%对60.5%、48.1%对45.9%、39.1%对27.5%)。ARL在年轻人中更常见;1年死亡率高。抗HIV治疗联合抗非霍奇金淋巴瘤治疗可显著改善ARL患者的预后。CHOP方案可能更适合ARL患者。

相似文献

本文引用的文献

4
Cancer statistics, 2015.癌症统计数据,2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验